Greetings and welcome to the Kezar Life Sciences Second Quarter 2020 Financial Results and Corporate Update Conference. [Operator Instructions]
It is now my pleasure to introduce your host, Miss. Celia Economides. Thank you. You may begin.
Thank you, Donna. Good afternoon everyone and welcome to Kezar Life Sciences conference call to discuss our clinical business and financial updates for the second quarter of 2020. With me on the call today from Kezar are John Fowler, Co-Founder and Chief Executive Officer; Christopher Kirk, President and Chief Scientific Officer; Noreen Henig, Chief Medical Officer; and Marc Belsky, Chief Financial Officer.
This afternoon we issued a press release detailing our second quarter 2020 financial results and updates for our clinical development programs. The press release is available on our website. I'd like to remind you that today's call is being webcast live on the investor relations page of Kezar's website, and a replay will also be available following today's call.
During the course of this call, we will make forward-looking statements based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties and our actual results may differ materially from those described. We encourage you to review the risk factors in our most recent Form 10-Q filed with the US Securities and Exchange Commission and available on our website. All statements on this call are made as of today based on information currently available to us. Except as required by law, we disclaim any obligation to update such statements, even if our views change.
With that, let me turn the call over to John.
Thank you, Celia. Good afternoon, everybody. And thank you for joining. First off, I hope that you and your loved ones are staying safe and healthy. These are trying times for all of us and I'd like to start by praising my team's amazing dedication and focus during this unprecedented health crisis. I've been incredibly impressed by my team's unrelenting efforts over the last several months, which underscores how deeply motivated we all are to help patients struggling with devastating autoimmune diseases and cancers.
With each passing quarter, my optimism grows for the profound potential for our novel mechanisms of action. Both of our drug candidates target master regulators of cellular function, whether by inhibiting the Immunoproteasome with KZR-616 or by disrupting the Sec61 Translocon with KZR-261. Over the last several months, we've continued to generate both clinical and preclinical data that speaks to the powerful role of our targets and the potential therapeutic benefits that we can unlock by targeting them with our exquisitely selected small molecule drugs. I'm excited for all of you to hear about some of these data from our new Chief Medical Officer, Noreen Henig, who I believe was drawn to join us based on the broad applicability and potential of our high science approach to make major impacts in the most difficult to treat diseases.
As you may recall, we have been evaluating our lead product candidate KZR-616
Senior Vice President of Strategy & External Affairs
Chief Executive Officer and Co-Founder
Noreen R. Henig
Chief Medical Officer
President & Chief Scientific Officer
Marc L. Belsky
Chief Financial Officer
We are pleased that you like our content! Sign Up now to access premium content for free, a very limited time offer.
Welcome! Create your account
You are successfully registered!
An activation link has been sent to your mail. Please activate and login.